As a researcher and consultant at Dialogic, I work on complex issues related to innovation and science policy, with a particular interest in biotechnology. Before joining Dialogic in 2025, I completed my PhD research in biomedical sciences at Utrecht University. To sharpen my analytical skills in policy, I also undertook training in policy evaluation at the Universities of Amsterdam and Maastricht during my PhD. Therefore, I combine extensive experience in quantitative and qualitative analyses with unique domain knowledge: as a former scientist, I understand the practice of science and innovation from the inside out. This background aligns well with my work for Dialogic, where I apply my scientific expertise in policy practice. During my PhD research, I discovered a new form of cell death after chemotherapy, which could potentially lead to new drugs that reduce the side effects of chemotherapy in the long term. Furthermore, I witnessed up close how rapidly biomedical knowledge and technologies evolve, and the significant impact these developments have on society, particularly in healthcare. Take for example CRISPR, a biotechnology that enables rapid and relatively simple genetic modifications. This technique is already leading to new therapies for cancer and genetic diseases, but also raises fundamental ethical questions. Do we want to allow genetic modifications in embryos, and what does that mean for society? Such issues also arise with technologies like AI, social media, and neurotechnology. The dynamic interplay between technological progress and ethical considerations greatly fascinates and motivates me to explore the impact of science, technology, and innovation on society.